Show simple item record

dc.contributor.authorRondy, Marc
dc.contributor.authorKissling, Esther
dc.contributor.authorEmborg, Hanne-Dorthe
dc.contributor.authorGherasim, Alin 
dc.contributor.authorPebody, Richard
dc.contributor.authorTrebbien, Ramona
dc.contributor.authorPozo Sánchez, Francisco 
dc.contributor.authorLarrauri, Amparo 
dc.contributor.authorMcMenamin, Jim
dc.contributor.authorValenciano, Marta
dc.identifier.citationEuro Surveill. 2018 Mar;23(9).es_ES
dc.description.abstractBetween September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.es_ES
dc.description.sponsorshipFunding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in individuals aged 65 years or more. ECDC has contributed to fund some study sites of the EU-PC study under the Framework contract No ECDC/2014/026 for the individuals aged less than 65 years. All study teams are very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams, regional epidemiologists who have contributed to the studies. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website www.gisaid.orges_ES
dc.publisherEuropean Centre for Disease Prevention and Controles_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectcase control studyes_ES
dc.subjectinfluenza vaccinationes_ES
dc.subjectinfluenza vaccine effectivenesses_ES
dc.subjectmulticentre studyes_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshEurope es_ES
dc.subject.meshEuropean Union es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfant es_ES
dc.subject.meshInfant, Newborn es_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtype es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshInfluenza B virus es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshInfluenza, Human es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPandemics es_ES
dc.subject.meshTreatment Outcome es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshSeasons es_ES
dc.titleInterim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studieses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderEuropean Union
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.relation.projectIDHorizon 2020 research and innovation programme under grant agreement No 634446es_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional